PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
42.50%
Net income growth 1.25-1.5x CRVO's 30.31%. Bruce Berkowitz would verify whether cost discipline or revenue gains drive the outperformance.
0.99%
D&A growth of 0.99% while CRVO is zero at 0.00%. Bruce Berkowitz would see a mild cost difference that must be justified by expansions.
No Data
No Data available this quarter, please select a different quarter.
-10.02%
Both cut yoy SBC, with CRVO at -66.48%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
66.71%
Slight usage while CRVO is negative at -212.37%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
AP growth well above CRVO's 20.31%. Michael Burry would be concerned about potential late payments or short-term liquidity strain relative to competitor.
-209.52%
Both reduce yoy usage, with CRVO at -67.33%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
100.00%
Well above CRVO's 39.72%. Michael Burry would worry about large intangible write-downs or revaluation gains overshadowing real performance.
51.97%
Operating cash flow growth above 1.5x CRVO's 0.52%. David Dodd would confirm superior cost control or stronger revenue-to-cash conversion.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.02%
Negative yoy issuance while CRVO is 100.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.